After criticisms, Biogen slashes price of its Alzheimer drug in half
CBSN
Biogen is slashing the price of its Alzheimer's treatment in half, months after it debuted to widespread criticism for an initial cost that could reach $56,000 annually.
Aduhelm, the first new FDA-approved Alzheimer's drug in almost two decades, is the first in a line of new drugs that promise to do what no other Alzheimer's treatment has managed: Slow the progress of the fatal brain-destroying disease, rather than just managing its symptoms.
The drugmaker said Monday it will cut the wholesale acquisition cost of the drug by about 50% next month. That means the annual cost for a person of average weight will amount to $28,200.

At ski resorts across the West this winter, viral images showed chairlifts idling over brown terrain in places normally renowned for their frosty appeal. Iconic mountain towns like Aspen, Colorado, and Park City, Utah, were seen with shockingly bare slopes, as the region endured a historic snow drought that experts warn could bring water shortages and wildfires in the months ahead. In:

A jury has found Elon Musk liable for misleading investors by deliberately driving down Twitter's stock price in the tumultuous months leading up to his 2022 acquisition of the social media company for $44 billion. But it absolved him of some fraud allegations, finding that he did not "scheme" to mislead investors. In:











